PMGC Stock (NASDAQ:ELAB)


RevenueFinancialsChart

Previous Close

$2.19

52W Range

$1.95 - $896.00

50D Avg

$2.64

200D Avg

$67.97

Market Cap

$2.98M

Avg Vol (3M)

$1.07M

Beta

-0.38

Div Yield

-

ELAB Company Profile


PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Nov 21, 2023

Website

ELAB Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23
AUSTRIA$234.80K
CANADA$158.60K
UNITED STATES$1.71M
VIET NAM$70.66K

Fiscal year ends in Dec 24 | Currency in USD

ELAB Financial Summary


Dec 24Dec 23Dec 22
Revenue-$1.71M$766.28K
Operating Income$-4.02M$-3.67M$-1.79M
Net Income-$-4.30M$-1.80M
EBITDA$-4.02M$-4.27M$-1.78M
Basic EPS-$-0.40$-0.19
Diluted EPS-$-0.40$-0.19

Fiscal year ends in Dec 24 | Currency in USD